Selected article for: "period study and treatment group"
Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma
  • Document date: 2018_8_30
    • ID: uzge50xu_29
    Snippet: Another secondary outcome of this study was change in rescue medication usage with treatment. Comparisons were done 3 ways: 1) within each group (BIS and MONT), usage at run-in (−2 weeks) was compared to usage at the end of the treatment period (12 weeks); 2) each subject in each group was analyzed over the study period (−2 weeks to 12 weeks) to determine any change in usage; 3) usage in the BIS group was compared to usage in the MONT group a.....
    Document: Another secondary outcome of this study was change in rescue medication usage with treatment. Comparisons were done 3 ways: 1) within each group (BIS and MONT), usage at run-in (−2 weeks) was compared to usage at the end of the treatment period (12 weeks); 2) each subject in each group was analyzed over the study period (−2 weeks to 12 weeks) to determine any change in usage; 3) usage in the BIS group was compared to usage in the MONT group at each time point (−2, 0, 4, 8 and 12 weeks). There was a significant decrease (P < 0.000) in rescue medication usage within each group (BIS and MONT) and in each subject in each group when analyzed over the study period (−2 to 12 weeks) (P = 0.002). However, there were no significant differences found when comparing usage in the BIS group to that in the MONT group

    Search related documents:
    Co phrase search for related documents
    • BIS group and MONT BIS group: 1, 2, 3, 4, 5, 6, 7, 8
    • BIS group and MONT BIS group rescue medication usage: 1
    • BIS group and MONT group: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • BIS group and MONT group usage: 1, 2
    • BIS group and rescue medication: 1, 2, 3
    • BIS group and rescue medication usage: 1, 2, 3
    • BIS group and run week: 1, 2, 3
    • BIS group and secondary outcome: 1, 2, 3, 4
    • BIS group and significant decrease: 1, 2, 3
    • BIS group and significant difference: 1, 2, 3, 4, 5, 6, 7
    • BIS group and study period: 1, 2, 3, 4, 5
    • BIS group and study secondary outcome: 1, 2, 3
    • BIS group and time point: 1, 2, 3
    • BIS group and time point MONT group usage: 1
    • BIS group and treatment period: 1, 2, 3, 4, 5
    • BIS group usage and group subject: 1
    • BIS group usage and MONT group usage: 1, 2
    • BIS group usage and time point MONT group usage: 1
    • BIS group usage and treatment period: 1, 2